CALCIMEDICA INC
CALCNASDAQ🏆 #4795 by market capEarnings Nov 11US Equity
$1.65▲ $0.30 (+22.22%)
Pre-market · at closeTrack CALC
Get earnings, price moves & breaking news on Telegram
24h▲ 22.2%
7d▲ 41.0%
14d▲ 46.0%
30d▲ 3.1%
ytd▼ 95.0%
1y▼ 89.1%
🏦Market Cap
$11M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
—
Insufficient data
Trading Snapshot
- Day Range
- $1.37 – $1.66
- 52-Week Range
- $1.00 – $36.00
- Volume (shares)
- 3,935
- Avg Volume (shares)
- —
- Shares Outstanding
- 6.8M
- Next Earnings
- 2026-11-11
Fundamentals Snapshot
- Annual Revenue
- —
- Last Q Revenue
- —
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-1.34
- Dividend Yield
- —
- Dilution (1yr)
- +17.6%
CALCIMEDICA INC
CALCFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$23M▼ −4.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$21M▲ +0.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.0M▲ +17.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$2M▼ −$6M YoY
StockOtter · stockotter.spaceAbout CALCIMEDICA INC
CalciMedica, Inc., a clinical-stage biotechnology company headquartered in La Jolla, California, is focused on creating treatments for life-threatening inflammatory diseases that currently lack adequate therapies. The company's proprietary approach involves blocking calcium release-activated (CRAC) channels, a mechanism designed to modulate the immune system and protect against cellular and tissue damage in these severe conditions. Their primary experimental drug, Auxora, is an intravenously administered, proprietary CRAC channel inhibitor being developed for the treatment of acute pancreatitis, including its asparaginase-associated form, and acute kidney injury.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
💧Dilution★★★★★
Overall Score
Insufficient data
—/100
Analyst Ratings
ⓘConsensus
Buy
9 analysts
Strong Buy3
Buy4
Hold2
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.